Subscribe: Drug Policy
http://www.reason.com/topics/topic/144.xml
Added By: Feedage Forager Feedage Grade B rated
Language: English
Tags:
bill  dark web  drug  drugs  federal  law  laws  marijuana  medical marijuana  medical  policy  sessions  state  states  trump 
Rate this Feed
Rate this feedRate this feedRate this feedRate this feedRate this feed
Rate this feed 1 starRate this feed 2 starRate this feed 3 starRate this feed 4 starRate this feed 5 star

Comments (0)

Feed Details and Statistics Feed Statistics
Preview: Drug Policy

Drug Policy



All Reason.com articles with the "Drug Policy" tag.



Published: Tue, 27 Jun 2017 00:00:00 -0400

Last Build Date: Tue, 27 Jun 2017 13:59:26 -0400

 



LSD Microdosing: The New Silicon Valley Productivity Hack

Mon, 26 Jun 2017 14:21:00 -0400

Tech entrepreneur George Burke consumes a tiny amount of LSD (about a tenth of a typical dose) every morning before he goes to work.

He says "microdosing" subtly improves his cognitive functioning.

"I notice that my brain seems to be able to solve problems a little bit better than...before," says Burke, who runs a startup called Fuel that helps its clients custom tailor their diets to their unique genetic makeups.

The use of psychedelics as productivity and creativity hacks is deeply rooted in Silicon Valley culture. Burke was partly inspired to go public about his drug use by the late Steve Jobs, who told his biographer Walter Isaacson, "[t]aking LSD was a profound experience, one of the most important things in my life."

"People have to actually have to step up and state what they've been doing," says Burke.

Reason spoke with Burke and with James Fadiman, a scientist researching the effects of microdosing.

Watch the full video above.

Produced by Zach Weissmueller. Camera Alex Manning. Additional graphics by Meredith Bragg. Music by Kai Engel and Broke for Free.

Subscribe to our YouTube channel.

Like us on Facebook.

Follow us on Twitter.

Subscribe to our podcast at iTunes.




The Silk Road Is Dead, But the Internet's Illicit Drug Economy Is Alive and Well

Thu, 22 Jun 2017 16:42:00 -0400

Dark-web drug transactions increased 50 percent between 2013--the year the FBI shut down the Silk Road--and January 2016, according to a new report from the United Nations. The Silk Road may be dead, but the dark web drug economy is very much alive. "While drug trafficking over the darknet remains small, there has been an increase in drug transactions of some 50 per cent annually between September 2013 and January 2016 according to one study," the United Nations Office on Drugs and Crime notes in its annual report on global illicit-drug trends. "Typical buyers are recreational users of cannabis, 'ecstasy,' cocaine, hallucinogens and [novel psychoactive substances]." The increase in dark web transactions post-Silk Road has been documented before. "After Silk Road was taken down by the FBI in October 2013," the RAND Corporation reported last year, "it was only a matter of weeks before copycats filled the void." As of 2016, the research group had counted 50 "so-called cryptomarkets and vendor shops" where anonymous buyers and sellers could conduct transactions using Bitcoin and PGP encryption. (Several sites are now also accepting the cryptocurrency Ethereum.) Boston College sociologist Isak Ladegaard, meanwhile, noted a massive increase in sales directly following the arrest of Silk Road founder Ross Ulbricht in late 2013. In a recent interview with Wired, Ladegaard theorized that media coverage of the case essentially served as earned marketing for the dark web. More observations from the UN's report: While Global drug trafficking cases increased only slightly from 2013 to 2015, the Global Drug Survey of 2017 found the amount of product moving through the dark web has increased dramatically. Roughly 8 percent of global drug users acquired an illicit substance through the dark web in 2017, up from 4.7 percent in 2014. Perhaps due to the passage of the Psychoactive Substances Act in 2016, the UK has seen the biggest increase in crypto sales: In 2016, 18.3 percent of British users acquired drugs on the dark web, while 25.3 percent of users have in 2017. These numbers are probably off, but the trend is likely real. (Crypto buying is down slightly in the U.S.) "Vendors in countries in Asia seemed to be more involved in the wholesale business, while retail sales were dominated by vendors in North America and Europe." As I noted in my piece on steroids, Asia is a dominant supplier of raw chemicals used in making America's illicit drugs. (Americans tend to think of Mexico as our biggest supplier, but it's really just an intermediary.) Silk Road was, in hindsight, a relatively small operation. "Overall, the value of transactions in the eight markets that dominated the darknet in January 2016 was 2.6 times greater than that of transactions on the Silk Road market in September 2013, which dominated the darknet at that time." This is also not surprising. If Silk Road taught the drug community anything, it's not to put all of your Bitcoin supply in one dark wallet. Heroin is not a popular dark web drug: "When compared with the overall distribution of drugs in the United States and European Union markets, methamphetamine and heroin appear to be underrepresented on the darknet, while 'ecstasy' and 'psychedelics' (hallucinogens) are overrepresented in sales over the darknet." Cross-marketing between the open web and the dark web isn't mentioned in the U.N. report, but that may have been noted elsewhere. Several open web steroid forums, for instance, feature user handles shared by dark web vendors. Users will post in the open forums about new products--but not actually sell them there--because it's easier to market to a wide audience on the open web. I haven't seen anything quite so brazen in forums for other drugs, but posters in other places suggest to neophytes that setting up a cryptomarket account, buying bitcoin through conventional channels, and then tumbling that currency into a dark web account is a wiser (if more laborious) choice than trying to score mystery pills at a rave. I suspect the dark web [...]



Philando Castile's 'Audacity To Smoke Marijuana' in Front of Child Doomed Him, Says Cop Who Killed Him

Thu, 22 Jun 2017 13:45:00 -0400

The shooting death last summer of Philando Castile, a licensed-and-law-abiding gun owner and cafeteria manager, by a Minnesota policeman provoked outrage over police brutality, especially since Castile's girlfriend was able to livestream the horrific event. Castile was shot seven times as he reached for his license and even though his girlfriend's young daughter was sitting in the backseat of his car. The acquittal of St. Anthony Officer Jeronimo Yanez has led to a similar outpouring of anger, especially in light of dashcam footage that "shows a cop who panicked and killed an innocent man," in the words of Reason's Jacob Sullum. A transcript of Yanez's explanation of his state of mind should only fuel more public discussion and calls to action. From the Daily News: "I thought if he's, if he has the, the guts and the audacity to smoke marijuana in front of the five-year-old girl and risk her lungs and risk her life by giving her secondhand smoke and the front seat passenger doing the same thing then what, what care does he give about me," Yanez told the Bureau of Criminal Apprehension. Full transcript here. The mind boggles: Secondhand smoke as a license to kill? Yanez even acknowledges that the girl "was in my line of fire" but that he "directed his firearm down...as best I could" to avoid her. Yanez may face federal charges in the case and Castile's family plans to file a civil suit against him and the St. Anthony police force. Regardless of any of that, Yanez's mind-set is incredibly telling not simply of his personal psychology but of a national mental disorder induced and exacerbated by the decades-old drug war. The drug war is not simply a set of laws and criminal procedures. It's much more like the Cold War, what I call a "structuring event" in American life that touches every aspect of our culture, politics, and commerce. From a 2006 talk I gave at a Students for a Sensible Drug Policy conference, on the topic of "What Would a Sensible Drug Policy Look Like?": The drug war screws with everything that it touches, and it touches everything...What I want to do is try to create a post-prohibitionist mind-set, where we are no longer merely reacting to prohibition and trying to get rid of it, because in a way we become twinned with it.... When we talk about the Tour de France, we talk about drugs. When we talk about Major League Baseball, we talk about who's using them. Plan Colombia and a good chunk of our foreign policy is all about drugs. Hundreds of thousands of people are in jail because of drug policy. All of you [students] probably went through some form of bogus drug education program, all for no good reason. The real dead-end of this is...[found] in men's rooms in America. When you go and take a piss, there is a pretty good chance that the urinal cake holder, the thing that deodorizes it...says 'Say No To Drugs' on it.... The quick version of my sensible drug policy, of a post-prohibitionist policy, is that it would be smarter to regulate all drugs, including prescription drugs, somewhat like we do with alcohol.... Like drug warriors...we will need to stop imbuing inanimate objects with supernatural powers. The drug war is over, if we want it—to paraphrase a famous anti-Vietnam war slogan. The end of the war starts up here, in our heads, and then proceeds out to the actual America. The starting point for a sensible drug policy, a true post-prohibitionist mind-set that does not participate in any way with prohibitionist thinking, would be take seriously the credo of the Whole Earth Catalog..."We are as gods, and we might as well get good at it." Ironically, the first step to becoming gods may be to recognize that drugs are only one means among many for changing who we are, how we live, and what we will become. From the minute we're born, we are bombarded with messages and lessons about how drugs are bad, evil, and uniquely destructive; how they inherently give rise to criminality, violence, and mayhem; how we must forever be on the lookout for users, a[...]



Juries Can Acquit the Guilty, 9th Circuit Says, but 'There Is No Right to Nullification'

Tue, 20 Jun 2017 10:15:00 -0400

Advocates of jury nullification argue that jurors have both the power and the right to acquit a guilty defendant if they believe the law or its application is unjust. According to a recent ruling by a federal appeals court, they are half right. USA v. Kleinman involves an operator of medical marijuana dispensaries in California who was convicted of federal drug charges and sentenced to nearly 18 years in prison. Among other things, the defendant, Noah Kleinman, argued that the judge had improperly instructed the jury regarding nullification. The U.S. Court of Appeals for the 9th Circuit agreed but said the error was harmless because "there is no right to nullification." Here is what the judge told the jury: You cannot substitute your sense of justice, whatever that means, for your duty to follow the law, whether you agree with it or not. It is not for you to determine whether the law is just or whether the law is unjust. That cannot be your task. There is no such thing as valid jury nullification. You would violate your oath and the law if you willfully brought a verdict contrary to the law given to you in this case. The 9th Circuit had no problem with the first three sentences, which (not surprisingly) reflect the view of most judges and prosecutors: The jury's job is to determine the facts, not to judge the law. If a juror concludes beyond a reasonable doubt that a defendant's actions meet the statutory definition of the crime with which is charged, the juror's duty is to vote for conviction, even if he thinks the statute is unjust or that applying it to the defendant would be grossly unfair. "If Kleinman's jury had exercised its power to nullify, it presumably would have disregarded the court's instructions on federal drug law and the court's antinullification instructions," the appeals court said. "The court had no duty to make the jury aware of its power to nullify, and properly instructed the jury that it could not (1) substitute its sense of justice for its duty to follow the law, or (2) decide whether a law is just or unjust." But the 9th Circuit said the last two sentences of the jury instruction went too far by implying that a not-guilty verdict in such a case would be legally invalid and that jurors might be punished for it. "The court's statement that the jury 'would violate [its] oath and the law if [it] willfully brought a verdict contrary to the law given to [it] in this case,' may imply punishment for nullification, because 'violate your oath and the law,' coming from the court in a criminal trial, could be understood as warning of a possible violation with associated sanctions. Additionally, the statement that '[t]here is no such thing as valid jury nullification' could reasonably be understood as telling jurors that they do not have the power to nullify, and so it would be a useless exercise. While jurors undoubtedly should be told to follow the law, the statement that there is no valid jury nullification misstates the role of nullification because an acquittal is valid, even if it resulted from nullification." The appeals court nevertheless rejected Kleinman's argument that the erroneous jury instruction required reversal of his conviction. "It is not fundamentally unfair for a defendant to be tried by a jury that is not fully informed of the power to nullify," the court said, "or even that is stripped of the power to nullify, because there is no right to nullification. Although a jury should not be led to believe that jury nullification will result in punishment or an invalid acquittal, the court's misstatement by implication does not rise to the level of denial of Kleinman's due process rights." The decision, which was issued last Friday, also dealt with the proper application of the Rohrabacher/Farr amendment, a spending rider that bars the Justice Department from interfering with the implementation of state medical marijuana laws. Last year the 9th Circuit ruled that the amendment covers prosecution of medical marij[...]



This Bill Would Protect Medical Marijuana Suppliers From Jeff Sessions' Whims

Thu, 15 Jun 2017 08:30:00 -0400

Today a bipartisan group of senators plans to introduce a new version of the CARERS Act, which aims to protect medical use of marijuana in the 29 states that allow it. Among other things, the bill would provide a more permanent shield from prosecution and forfeiture than the Rohrabacher/Farr amendment, the spending rider that bars the Justice Department from interfering with the implementation of state medical marijuana laws. As Mike Riggs noted on Tuesday, Attorney General Jeff Sessions sent congressional leaders a letter urging them not to include the rider, which has to be reapproved each fiscal year, in the DOJ appropriations bill enacted last month. After Congress rejected Sessions' request, President Trump signed the bill but issued a statement implying that he might ignore the rider if that was necessary to meet his "constitutional responsibility to take care that the laws be faithfully executed." Such a scenario is hard to imagine, since those laws include the restrictions imposed by the Rohrbacher/Farr amendment. It's not clear how significant the letter and the signing statement are as indicators of Sessions' intentions because the Obama administration also opposed the Rohrabacher/Farr amendment and urged courts to read it narrowly. Under Eric Holder, the DOJ argued that the rider covered only direct legal challenges to medical marijuana programs. Last year the U.S. Court of Appeals for the 9th Circuit rejected that interpretation, ruling that the rider also prohibits the prosecution of people who supply or possess marijuana for medical use in compliance with state laws. Despite opposing the rider, the Obama administration eventually settled on a policy of prosecutorial restraint, generally tolerating state-licensed marijuana businesses, including those serving recreational consumers, unless they violated state law or impinged on "federal law enforcement priorities." Sessions has said he agrees with much of that policy but thinks it was not applied vigorously enough—an attitude that, along with his well-known anti-pot prejudices, could signal a crackdown. But so far Sessions has not tried to shut down state-legal cannabusinesses, which federal prosecutors could easily do simply by writing some threatening letters. Nor has he challenged state marijuana laws in federal court, even as lawsuits by other parties (neighboring states, local law enforcement officials, and anti-drug activists) have fizzled out. Sessions' restraint may have something to do with positions taken by his boss before and after the presidential election. During the campaign, Trump repeatedly said states should be free to legalize marijuana, and he has consistently said medical use should be permitted. A crackdown on medical marijuana would break Trump's promises, and it would stir up a lot of political trouble with no obvious upside, other than gratification of Sessions' prohibitionist impulses. Still, it would be nice to have some lasting protection from the attorney general's whims. In addition to prohibiting federal prosecution of patients and their suppliers, the CARERS Act would eliminate some obstacles to marijuana research, allow doctors employed by the Veterans Health Administration to recommend medical marijuana in states where it is legal, and remove cannabidiol, a nonpsychoactive but therapeutically promising component of marijuana, from Schedule I, the most restrictive category under the Controlled Substances Act. The bill, which was originally introduced in 2015, no longer includes provisions that would have removed marijuana from Schedule I and protected banks that serve the cannabis industry. Those provisions were cut in the hope of attracting broader support for the bill. The initial sponsors this year include Sen. Mike Lee (R-Utah) and Lisa Murkowski (R-Alaska), who did not back the 2015 version, as well as Sens. Rand Paul (R-Ky.), Cory Booker (D-N.J.), Kirsten Gillibrand (D-N.Y.), and Al Franken (D-Minn.), who were [...]



In Private Letter, Jeff Sessions Asks Congress for Permission to Go After Medical Marijuana

Tue, 13 Jun 2017 12:05:00 -0400

In a previously undisclosed letter sent last month, Attorney General Jeff Sessions asked lawmakers not to renew a rider that blocks the Justice Department from interfering with the implementation of state-level medical marijuana laws. "I believe it would be unwise for Congress to restrict the discretion of the Department to fund particular prosecutions," Sessions wrote, "particularly in the midst of an historic drug epidemic and potentially long-term uptick in violent crime. The Department must be in a position to use all laws available to combat the transnational drug organizations and dangerous drug traffickers who threaten American lives." The letter—dated May 1, 2017, and addressed to Sens. Mitch McConnell and Charles Schumer and Reps. Paul Ryan and Nancy Pelosi—was obtained by Massroots.com's Tom Angell. It specifically asks that Congress not renew the Rohrabacher-Farr amendment, passed in 2014. Barack Obama's Justice Department challenged the amendment last year, and it lost in the 9th Circuit Court of Appeals. That means if Sessions wants to go after medical marijuana, he'll need Congress to remove Rohrabacher-Farr from the next appropriations bill. Congress should tell him to get lost. As the Washington Post's Christopher Ingraham writes, emerging evidence suggest that state-legal medical marijuana reduces the use of opioids. Meanwhile, the one example Sessions cites of traffickers taking advantage of state law actually undermines the idea that his department needs more power. The case Sessions mentions in his letter involves a group of Colorado residents who allegedly grew pot off the books in order to sell it in states where marijuana is not yet legal. Several members of the alleged conspiracy were able to obtain licenses from the Colorado Marijuana Enforcement Division. Yet they're accused of violating Colorado law, which prohibits the transportation of cannabis products across state lines. This is why Colorado's Marijuana Enforcement Division is working with the Drug Enforcement Administration to investigate the group: Neither agency condones interstate marijuana trafficking. Sessions seems to think that because several of the alleged conspirators were able to get pot licenses before they allegedly broke state law, the Justice Department needs a blank check to wreak havoc in medical marijuana states. That's one clumsy bait-and-switch. It's also in keeping with Sessions' ratcheting-up of the federal war on everything. He's instructed federal prosecutors to seek the maximum penalty against non-violent, low level drug offenders; attempted to enlist local police for federal immigration enforcement, and is seeking to erode online privacy protections in the name of freeing modern slaves.[...]



City of Fontana Tries to Restrict Californians' Pot Growing Rights, Gets Sued with Help of ACLU

Tue, 06 Jun 2017 19:20:00 -0400

California's Adult Use of Marijuana Act (AUMA) passed into law last year with 57 percent support. The city of Fontana in California reacted in February to the law, known on the ballot as Proposition 64, by passing Ordinance 1758, which restricts the rights to grow marijuana for personal use granted in that state law. This week, the American Civil Liberties Union (ACLU) of Northern California and the Drug Police Alliance (DPA) filed a lawsuit in California Superior Court in San Bernardino County challenging the Fontana ordinance. In Harris v. Fontana, plaintiff Mike Harris, a 61-year-old Fontana resident (and a former union iron worker and registered nurse), claims marijuana helps him with pain resulting from his prosthetic hip and shoulder reconstruction. Harris wishes to grow his medicine for himself in his Fontana home as is his right under AUMA, but says Fontana's ordinance is preventing him. (The lawsuit notes that local support for the state law was also high, with 53.5 percent of the city of Fontana and 52.5 percent of San Bernardino County voting for it.) The AUMA does allow cities to reasonably regulate marijuana growing, but also insists that "no city … may completely prohibit persons" from cultivating marijuana "inside a private residence … that is fully enclosed and secure." The suit argues that Fontana's policies in Ordinance 1758 amount to an illegitimate interference in the rights protected by AUMA. Specifically, the suit claims that elements of the ordinance such as demanding a local permit that costs more than $400, forcing applicants to make "statements that admit to a violation of federal law and that federal authorities could easily obtain," and forcing Fontanans to "submit to (and pay for) a warrantless search of their homes by government agents" are "transparently designed to deny residents the benefits and rights conferred by the AUMA." The ordinance also forces citizens to "submit to (and pay for) an illegal, costly, and wholly unnecessary criminal database search" in order to illegitimately prevent "some citizens with criminal records from growing under any circumstances." The suit notes, with many specific examples, that Fontana politicians very clearly stated that the purpose of the ordinance was to be "as restrictive as possible" toward pot cultivation in their city. Under AUMA, the lawsuit says: "it shall be lawful under state and local law, and shall not be a violation of state or local law, for persons 21 years of age or older to … (3) Possess, plant, cultivate, harvest, dry, or process not more than six living marijuana plants and possess the marijuana produced by the plants." Other than limiting the lawful activity to adults aged 21 and over, the AUMA places no further restrictions on who may engage in activities such as possession and cultivation of nonmedical marijuana, and makes such behavior affirmatively lawful under state and local law. The various requirements to get a permit to grow pot in Fontana, which the suit lays out in detail: are plainly intended to make it unreasonably difficult and expensive for persons desiring to cultivate marijuana to do so. Many residents of Fontana will be unable to afford to dedicate a separate room in their home entirely to the cultivation of six or fewer marijuana plants, or to undertake the construction necessary to create a separate, locked room accessible by a single door. Occupants of single rooms, in-law units, studios, one bedroom apartments, and other smaller homes may be denied a license based solely on the design of their homes. Residents who have unpaid municipal fines or fees are also denied permission to cultivate, even though this has no reasonable relation to public health or safety, let alone to the cultivation of marijuana. The requirement to submit to fingerprinting "for a search in the California Department of Justice's LiveScan criminal records database is an[...]



This is Your Brain on Acid (Seriously)

Thu, 01 Jun 2017 16:45:00 -0400

The study of psychedelics is "bringing psychotherapy and medicine together," says David Nutt, a neuropsychopharmacologist at Imperial College London and a co-author of the first imaging study looking at the effects of LSD on the human brain. "Drug-assisted psychotherapy is going to be the great advance in the [field in the] next 20 years." In 2009, Nutt was fired from his job as a drug adviser to the British government after he made comments about ecstasy and other illegal drugs being less dangerous than alcohol and even horseback riding. Reason's Zach Weissmueller sat down with Nutt at the Psychedelic Science 2017 conference in Oakland to talk about the results of his groundbreaking imaging study, what he learned about drug policy while working as a science adviser for the English government, and what he sees for the future of psychedelics and mental health treatment. Produced by Zach Weissmueller Camera by Alex Manning. Additional graphics by Meredith Bragg. Music by Sergey Cheremisinov. Subscribe to our YouTube channel. Like us on Facebook. Follow us on Twitter. Subscribe to our podcast at iTunes. This is a rush transcript—check all quotes against the audio for accuracy. Zach: Hi I'm Zach Weissmueller for Reason. We're here at the Psychedelic Science 2017 conference in Oakland. I'm here with David Nutt. He is the Edmond J. Safra Professor of Neuropsychopharmacology at the Imperial College of London. Thank you very much for joining us Dr. Nutt. Dr. Nutt: Good to be here. Zach: You were the chief drug advisor in England. Something happened, could you just tell us that story? Dr. Nutt: For nine years I was the head of the group that assessed drug harms for the government and over that time we did an enormous amount of research into the comparative harms of drugs. As a result of that I discovered, somewhat to my surprise, that alcohol was actually the most harmful drug in the UK. The drugs that politicians like to get hysterical about like cannabis and MDMA, Ecstasy, are comparably much less harmful. So then I started explaining that to the government saying, "Well, our drug laws are wrong. Actually putting people in prison for cannabis possession is not fair because alcohol is more dangerous." They did not want to hear that. They said, "Stop saying that." Zach: They sacked you for looking at the data and giving your analysis. Isn't that your job as the Drug Advisor of the government? Dr. Nutt: Well, I thought it was my job, yeah. I thought my job was to evaluate evidence and make recommendations, but they said, "Oh no, no, he's doing more than that. He's trying to change government policy." I said, "I thought that's what all scientists did." If the evidence suggests the policy's wrong then we want to change the policy, once you been sacked you've got no comeback. Although, of course, what did happen was that it brought the whole issue of drug harms and comparative harms in the public domain. There was an enormous outcry and a lot of scientists wrote petitions saying they should reinstate me. I became famous and the whole drug debate went viral. So for the first time we actually had a proper debate. The government shot itself in the head really because it went from drugs being something you didn't talk about to drugs being something everyone wanted to talk about. Zach: Why was that such a taboo thing to say? Dr. Nutt: There are some things which you can't have what you might call a balanced debate because everyone has a strong view. Drugs are bad, drugs are bad, War on Drugs, we've got to get rid of drugs. That was our policy the same way it's been American policy. Anyone challenging that was actually really cutting to the heart of the prejudices which underpin the British establishment. And it went right through government. It went certainly through both the right wing and the left wing parties. Zach: It's my understanding that t[...]



California Senate Passes Bill Easing Up on Some Drug Sentencing

Tue, 16 May 2017 16:45:00 -0400

(image) With the news last week that Attorney General Jeff Sessions is telling federal prosecutors to ramp the war on drugs right back up, expect to see some resistant states publicizing efforts to do the opposite.

That's happening in California, where the state's Senate this week approved SB 180, 22-13. Nicknamed the Repeal Ineffective Sentencing (RISE) Act, the bill eliminates a particular drug-related sentencing enhancement under California law.

When a person is arrested for drug sale or possession for drug sale, the state requires their sentence be enhanced by three years for each previous felony conviction for violating similar laws, even if those previous convictions didn't result in jail time.

SB 180, sponsored by Sens. Holly Mitchell and Ricardo Lara, both Democrats, would eliminate the mandated sentence enhancements, except for one that applies when the felon gets minors involved in the trade.

Even though the legislation was obviously in the works for some time, supporters of the bill cited Sessions' recent call for tougher drug sentencing on the federal level as a concern, according to the Los Angeles Times.

And yes, apparently Republicans attempted crime fearmongering to try to stop it, pointing to the case of a cop in Whittier killed by a parolee with a lengthy history of crime. But that gentleman had a history of violent criminal behavior and parole violations. He was not a guy solely in jail over drug dealing. The assumption that the mandatory minimums and sentence enhancements are necessary to go after the violent criminals ignores the lengthy history and data showing these laws often swoop up non-violent, low-level criminals for long prison sentences.

The bill has many activist group co-sponsors, including the American Civil Liberties Union and the Drug Policy Alliance. Read the bill here. It is on its way to the Assembly now.




Iowa Expands Medical Marijuana Access; Looks to Strike Deal With Minnesota for Quicker Access

Tue, 16 May 2017 12:36:00 -0400

Iowa Gov. Terry Branstad on Monday signed a bill to expand access to medical marijuana in his state, but it might take as long as 18 months before patients with cancer and other diseases can get the drug in Iowa, as the state has to find growers and license distributors. In the meantime, Iowans might be able to travel to Minnesota to obtain medical marijuana, under a proposed agreement that would be the first of its kind in the country. "Iowa is trying to provide an innovative path to help patients obtain relief while the state gets its own system up and running," says Kate Bell, an attorney with Marijuana Policy Project, a national pro-legalization nonprofit. A component of the bill signed by Branstad directs state official in Iowa to contact Minnesota's Department of Health with the intention of opening a sharing agreement between the two states. Iowa Speaker of the House Linda Upmeyer (R-District 54) told the Associated Press last week that a deal between the two states could allow Iowans to have access to medical marijuana while the state is going through the process of setting up its own network of growers and distributors. "It's providing access to Iowans and doing it as quickly as we can," Upmeyer told the AP. "I just want to be sure if we have a tough time finding a grower, we have another source available." Minnesota would have to agree. A spokesman for the Minnesota Department of Health's medical cannabis program told Reason that the state legislature would have to change the rules to allow Iowans to access the drug in Minnesota. Minnesota Speaker of the House Kurt Daudt (R-District 31A) told the AP that he sees the potential for a sharing agreement with Iowa that would be "mutually beneficial thing" because it would allow manufacturers in Minnesota to find more customers. If Minnesota changes its rules along the lines of what has been floated by Upmeyer, the bilateral agreement between the two states would be unique, but it would not be the first time that a state has allowed out-of-state residents access to medical marijuana. According to the Marijuana Policy Project, 14 of the 29 states with legal medical marijuana allow some form of "reciprocity" to accept out-of-state marijuana prescriptions. The MPP says it's important for states to include reciprocity agreements in their medical marijuana laws so patients can safely obtain the drug while visiting a different state or, as is the case in Iowa, while waiting for dispensaries to be licensed and become operational in their home states. Despite the fact that medical marijuana is now legal in a majority of states, marijuana remains on the federal government's Schedule I list—a classification given to drugs with "no currently accepted medical use and a high potential for abuse," according to the Drug Enforcement Administration. There are concerns about a potential crackdown on state-level legalization efforts by the U.S. Department of Justice, particularly in the wake of Attorney General Jeff Sessions' comments last week encouraging prosecutors to seek harsher penalties for drug traffickers. But moving medical marijuana from Minnesota to Iowa is unlikely to get you in any more trouble than if you'd been transporting it within Minnesota. That's because of a 2005 Supreme Court ruling (Gonzalez v. Raich) that gave Congress the authority to regulate even intra-state non-commercial cannabis activity. "So the fact that it's interstate doesn't make it 'more illegal,'" Bell told Reason via email. Since patients can go directly from one state to the other—without having to pass through any states where medical marijuana is illegal—there should be limited law enforcement issues, she said. Since legalizing medical marijuana in 2015, Minnesota has seen steady growth in the number of patients accessing the drug. As of March 201[...]



Trump's Medical Marijuana Threat Contradicts the Law and His Own Position

Mon, 08 May 2017 08:00:00 -0400

The appropriations bill that President Trump signed on Friday renews a rider that bars the Justice Department from interfering with the implementation of state laws allowing medical use of marijuana. But Trump signaled in a signing statement that he may decide to ignore that restriction, known as the Rohrabacher-Farr amendment, notwithstanding his repeatedly expressed support for medical marijuana and for respecting state policy choices in this area. "Division B, section 537 provides that the Department of Justice may not use any funds to prevent implementation of medical marijuana laws by various States and territories," Trump says in the signing statement. "I will treat this provision consistently with my constitutional responsibility to take care that the laws be faithfully executed." The implication is that Trump's duty to enforce the federal ban on marijuana, which makes no exception for medical use, could compel him to disregard the bill's limits on the use of DOJ money. That position makes no sense, since Trump's duty to take care that the laws be faithfully executed includes this law, which explicitly tells the Justice Department to refrain from interfering with state medical marijuana programs. Last August the U.S. Court of Appeals for the 9th Circuit ruled that the Rohrabacher-Farr amendment prohibits the Justice Department from prosecuting medical marijuana suppliers who comply with state law, and the same analysis would also apply to civil forfeiture actions. As Steve Bell, a senior adviser at the Bipartisan Policy Center, told Bloomberg News, "It is the constitutional prerogative of the Congress to spend money and to put limitations on spending." Bell described Trump's signing statement as "an extremely broad assertion of executive branch power over the purse." Trump is not only trying to usurp the congressional power to decide how taxpayers' money will be spent; he is threatening to interfere with the autonomy that states are supposed to have under the 10th Amendment. He is also contradicting his own position both before and after his election. At the Conservative Political Action Conference in March 2015, Trump said he was leery of legalizing marijuana for recreational use, but "medical marijuana is another thing." He said he was "100 percent" in favor of medical use. He made similar statements while campaiging in Nevada that October, in New Hampshire the following January, and in Michigan two months later. White House Press Secretary Sean Spicer reiterated Trump's support for medical marijuana in February. "There's two distinct issues here: medical marijuana and recreational marijuana," Spicer said. "I think medical marijuana, I've said before that the president understands the pain and suffering that many people go through who are facing especially terminal diseases and the comfort that some of these drugs, including medical marijuana, can bring to them. And that's one that Congress, through a rider...put in an appropriations bill saying the Department of Justice wouldn't be funded to go after those folks. There is a big difference between that and recreational marijuana." The rider to which Spicer referred is the very one Trump has now signaled he may flout. Mind you, Trump has said states should be free even to legalize marijuana for recreational use, although he does not think that's a good idea. In the case of medical marijuana, he has taken the further step of saying he supports the policy, which makes this latest threat all the more puzzling. "Donald Trump continues to send mixed messages on marijuana," says Michael Collins, deputy director of the Drug Policy Alliance. "After stating during the campaign that he was '100 percent' in support of medical marijuana, he now issues a signing statement casting doubt on whether his admini[...]



Marijuana Policy in the Trump Era

Thu, 04 May 2017 12:00:00 -0400

Attorney General Jeff Sessions has called marijuana "only slightly less awful" than heroin. But with cannabis legal in 28 states and Washington, D.C., it's clear that federal and state drug policies are at odds. Does the Trump administration want to stop marijuana legalization? How is California dealing with the uncertainty that surrounds this legal industry? What can we expect in the next four years and beyond?

On April 20, 2017, Reason hosted a panel of experts interested in the state of marijuana legalization. Lynne Lyman, California State Director of the Drug Policy Alliance, Diane Goldstein of Law Enforcement Action Partnership, Kenny Morrison, president of the California Cannabis Manufacturer's Association and founder of the edibles manufacturer VCC Brands, and Jeff Chen, a researcher at the UCLA David Geffen School of Medicine, answered questions from Reason TV's Zach Weissmueller as well as viewers watching live on Facebook about the future of marijuana in America, what California's market might look like, how law enforcement is reacting to the changes, and the current state of marijuana science.


Hosted by Zach Weissmueller. Edited by Alex Manning. Camera by Manning and Paul Detrick.

Subscribe to our YouTube channel.

Like us on Facebook.

Follow us on Twitter.

Subscribe to our podcast at iTunes.




Injection Facilities a Bold Remedy for Overdose Deaths

Thu, 27 Apr 2017 00:01:00 -0400

Addiction to opioids is hazardous to your health. To most people, this may sound like an obvious and inescapable reality. If your chief priority is staying cool, the thinking goes, you don't move to Phoenix. If you really want to stay alive, you don't use heroin. But humans have created innumerable places in Phoenix where it's possible to minimize personal contact with searing heat. Humans have also created places where it's possible to inject opioids at relatively low risk. Heroin users have long been susceptible to life-threatening diseases such as AIDS and hepatitis, which are spread through shared syringes. In recent years, those who use heroin or prescription opioids have also faced an increasingly common and more immediate peril: sudden death from overdose. In 2015, more than 33,000 Americans died of overdoses involving these drugs—nearly triple the number in 2002. That growing epidemic is one reason that life expectancy among whites actually declined last year. It's not hard to figure out why opioid dependence can lead to the morgue. Users may overdose because their heroin has been adulterated with other, more powerful drugs. They may combine opioids with alcohol or sedatives, aggravating the risk. They often shoot up alone or with other users, meaning they may have no one who can help them if things go wrong. The best way to reduce the toll is dissuading people from opioid use. But some people are drawn to intoxicating substances, and once they become dependent, they find it hard to abstain even if they would like to—which many don't. So the question becomes how to prevent inveterate users from dying. Not everyone thinks this objective is commendable. In the 1990s, drug users were contracting and dying of AIDS (and infecting their sexual partners) after shooting up with dirty syringes. But a lot of people, including President Bill Clinton, resisted efforts to expand access to clean needles. Like giving condoms to teens, this was seen as a false solution that would only encourage people to engage in risky behavior. Wrong. Making sterile needles available, it turned out, averted disease and saved lives without generating more addiction. Let drug users get the means to protect themselves, and many of them will take it. Self-destructiveness is not necessarily their goal. A comparable approach can avert overdose deaths. One tool is naloxone, a drug that quickly neutralizes the effects of opioids, reversing overdoses. Emergency rooms keep it on hand. Ambulances carry it. Some police departments equip officers with supplies. Another solution is coming to King County, Washington, which includes Seattle: safe injection facilities where people dependent on drugs can use them in clean conditions, without fear of arrest, under the supervision of health care workers. Those users who are ready to go straight will also get help finding treatment. Though it's never been done in the United States, it's a well-tested idea. The Drug Policy Alliance says these sites have been opened in some 100 cities around the world. They have spread because they work. Insite, which operates a venue in Vancouver, just over the Canadian border from Seattle, says 3 million injections have taken place there. Nearly 5,000 overdoses have been reversed, without a single overdose death. A review in the medical journal Drug and Alcohol Dependence found these facilities have been effective in fostering safer practices and reducing overdoses. Contrary to fears, they have not served to "increase drug injecting, drug trafficking or crime in the surrounding environments." Aside from the benefits to drug users, there are benefits to everyone else. The safe injection sites succeeded in curtailing public drug use and the presence of syri[...]



Why LSD Trips Last Forever, What Happens When You Inject Psilocybin

Wed, 26 Apr 2017 17:25:00 -0400

The world's leading researchers of psychedelic drugs met in Oakland, Calif., this past weekend at Psychedelic Science 2017, sponsored by the Multidisciplinary Association of Psychedelic Science (MAPS). I attended for for a story I'm working on about MDMA-assisted therapy, and thought I'd share some items from my notebook. Why do LSD trips last so long? Psilocybin and MDMA are both active in the body for two to three hours when administered in tens of milligrams. LSD, meanwhile, is administered in micrograms (1 mcg is .001 mg) and yet the drug experience can exceed eight hours. UNC-Chapel Hill's Dave Nichols, a medicinal chemist who's been studying psychedelics for decades, shared some new research that explains why. Imagine a carnivorous pitcher plant. That's the 5-HT2B serotonin receptor. Lysergic acid diethylamide, LSD, is a fly. Instead of attaching to the top of the receptor, the LSD molecule gets pulled inside and the top of the receptor closes around it. Basically, LSD trips last forever because the drug gets trapped in a brain cage. (Nichols' team published their findings in January. You can read more about them here.) What happens when you inject psilocybin? The psilocybin-assisted therapy study conducted by Johns Hopkins University--which found that moderate and high doses of psilocybin, in conjunction with psychotherapy, reduced anxiety and depression in cancer patients--used gel caps as the method of administration. Most recreational users just eat the mushrooms or brew them into tea. Over in Europe, however, researchers have experimented with intravenous administration. Apparently, it's like "rocketing [someone] out of a cannon"; the come-up takes place over roughly a minute, rather than half an hour. Well, duh. Except, at a Q&A later in the day, Nichols revealed LSD doesn't work any quicker when administered via IV. It truly is the Good Friday mass of psychedelic drugs. Prohibition makes this kind of research stupidly expensive: The Imperial College of London pays 1,500 British Pounds per dose of UK Home Office-approved psilocybin, according to researcher Leor Roseman, who noted that street prices are a fraction of that. (The ICL is currently doing a ton of interesting psychedlelic research right now.) I'm not sure how easy it is to obtain isolated psilocybin on the black market, but the mushrooms themselves grow on cow shit and dead plant matter. Stateside, dried psilocybin shrooms go for about $5-$10 per gram, according to various mycophile message boards and my own independent research. The most common (and cheapest) strains contain about .6 mg of psilocybin per gram of dry weight, and more exotic (read: expensive) strains have as much as 1.6 mg per gram. The Home Office essentially charged the ICL a penalty for studying a drug that should never have been banned. This kind of oblique research penalty is not unique to psilocybin, or to the UK. Cannabis researchers in the U.S. have to buy their bud from NIDA's monopoly operation, and it is not quality stuff. Psychedelic researchers are cautiously optimistic about Scott Gottlieb at FDA: Gottlieb, Trump's nominee for head of the Food and Drug Administration, has said he'd like to speed up the drug approval process, perhaps using more flexible clinical trial designs. What does this mean for MAPS, currently sponsoring clinical trials for MDMA-assisted psychotherapy? MAPS clinical sites recently completed stage two trials, and the group is now negotiating stage three protocols with the FDA. All they really need is for the agency to treat them like it would any other sponsor of a new drug application. That may sound like a small ask, but the FDA's history with psychedelic researchers is replete with periods of capr[...]



West Virginia Becomes the 29th State to Allow Medical Marijuana Use

Thu, 20 Apr 2017 09:45:00 -0400

Yesterday West Virginia Gov. Jim Justice signed a bill that makes his state the 29th to allow medical use of marijuana. West Virginia is the sixth state to legalize medical marijuana in the last year and the third (along with Ohio and Pennsylvania) to do so through the legislature. In the other three states—Arkansas, Florida, and North Dakota—voters approved ballot initiatives authorizing medical marijuana last November. West Virginia's new law recognizes marijuana as a treatment for patients with terminal illnesses or any of 14 specified conditions, including cancer, HIV/AIDS, epilepsy, multiple sclerosis, Crohn's disease, post-traumatic stress disorder, and intractable pain. Patients whose doctors recommend marijuana will be able to obtain it in the form of pills, oils, gels, creams, ointments, tinctures, liquids, and vaporizable extracts from state-regulated dispensaries. The dispensaries will not sell buds for smoking or marijuana edibles, although patients can prepare their own at home. The law does not allow home cultivation, and patients can legally possess no more than a month's supply at a time. "This legislation is going to benefit countless West Virginia patients and families for years to come," says Matt Simon of the Marijuana Policy Project (MPP), a West Virginia native. "Medical marijuana can be effective in treating a variety of debilitating conditions and symptoms. It is a proven pain reliever, and it is far less toxic and less addictive than a lot of prescription drugs. Providing patients with a safer alternative to opioids could turn out to be a godsend for this state." One downside to West Virginia's law is a new standard for driving under the influence of marijuana that erroneously equates impairment with a blood THC level of three nanograms per milliliter. That's even lower than the unfair and unscientific five-nanogram cutoff that Colorado and Washington adopted when they legalized marijuana for recreational use. As MPP notes, West Virginia's DUID standard "could make it illegal for some patients to ever drive, since many patients have THC levels at this amount or greater many hours or days after last administering cannabis." West Virginia's rules put it on the less liberal end of a medical marijuana spectrum that ranges from highly permissive (e.g., California) to highly restrictive (e.g., New York). Eight of the 29 medical marijuana states also allow recreational use. Medical use was approved by ballot initiative in 14 of those states, beginning with California in 1996. In the rest, as in West Virginia, medical marijuana laws originated in the state legislature. Another 18 states have approved medical marijuana laws that MPP deems "ineffective because they are either unworkable or exceptionally restrictive." These laws allow use of specific cannabis products—typically low-THC, high-CBD extracts—and often do not provide a way to legally obtain them. But if you count those 18 states, MPP says, "only three states—Idaho, Indiana, and Kansas—have not approved any form of medical marijuana law." Although the federal government still does not recognize any legitimate use for marijuana, surveys find strong popular support for letting patients have access to it. A Quinnipiac University Poll conducted in February and a Marist Poll conducted last month put support for medical marijuana at 93 percent and 83 percent, respectively. In both surveys, large majorities of both Republicans and Democrats favored medical access, as does President Trump. Even his attorney general, arch-prohibitionist Jeff Sessions, concedes that "dosages can be constructed in a way that might be beneficial."[...]